Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Gilead sciences, inc. save search
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.16 -9.38% -10.34% 340K
|
Professional, Scientific, and T...
|
| O: 200.47%
H: 0.52%
C: -43.75%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.33%
H: 0.85%
C: 0.0%
il-12 license program agreement
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.33%
H: 0.85%
C: 0.0%
year financial results
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.34%
H: 0.13%
C: -0.23%
yescarta fda t-cell change approval therapy
Global Pseudomonas Aeruginosa Infection Treatment Market Report 2024-2034: Rising Antibiotic Resistance Drives Demand for Pseudomonas Aeruginosa Infection Treatments
Published: 2024-01-17 (Crawled : 02:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.49%
H: 0.18%
C: 0.04%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.08%
H: 0.1%
C: -0.18%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.12%
H: 0.77%
C: 0.27%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.19%
H: 0.87%
C: 0.76%
report infection treatment global market
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
lyn-005 positive schizophrenia therapeutics study
Assembly Biosciences Provides Anticipated Development Milestones for 2024
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
ASMB | $13.64 2.33% 2.27% 11K
|
Health Technology
|
| O: 1.84%
H: 0.73%
C: -2.44%
Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.66%
H: 0.0%
C: -0.12%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -2.93%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.31%
H: 0.39%
C: -0.44%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.18%
H: 0.5%
C: -0.46%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.78%
H: 5.15%
C: 2.81%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.52%
H: 0.58%
C: 0.05%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.34%
H: 1.02%
C: 0.59%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.57%
H: 1.36%
C: 1.04%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.06%
H: 0.18%
C: -1.06%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.24%
H: 2.03%
C: 1.49%
patent report global market
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.77%
H: 1.52%
C: 0.58%
yescarta t-cell response therapy
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.95%
H: 0.72%
C: -0.5%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 6.34%
H: 2.04%
C: 0.93%
presentation car-t results
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
Published: 2023-10-20 (Crawled : 10:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.38%
H: 0.44%
C: -1.19%
sunlenca hiv
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
Published: 2023-10-19 (Crawled : 10:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.75%
H: 1.01%
C: -0.8%
biktarvy treatment hiv
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.01%
H: 0.3%
C: -0.99%
europe sciences hiv program trial
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities
Published: 2023-09-09 (Crawled : 04:20) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
report antiviral therapeutics market
Everest Medicines Announces Interim Results for First Half of 2023
Published: 2023-08-24 (Crawled : 01:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.5%
H: 0.45%
C: -0.86%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.27%
H: 1.15%
C: -1.19%
CALT | $17.65 -2.4% 4K
|
Health Technology
|
| O: -4.72%
H: 0.0%
C: 0.0%
results
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
Published: 2023-08-21 (Crawled : 13:20) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.28%
H: 0.78%
C: 0.36%
aml
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
Published: 2023-07-20 (Crawled : 21:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.76%
H: 1.53%
C: 0.48%
hepatitis grant program funding
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-07-14 (Crawled : 14:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.13%
H: 1.34%
C: 0.76%
covid-19 veklury fda renal treatment dialysis
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.28%
H: 0.04%
C: -1.1%
trodelvy chmp breast positive cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.